Tracking changes in brain areas related to movement and balance with non-invasive technique could lead to drugs to combat the condition, neuroscientists have revealed.
The researchers used functional magnetic resonance imaging (fMRI) to reveal areas where Parkinson’s and related disorders causes progressive decline.
Parkinson’s affects one in 500 people, causing involuntary shaking of certain parts of the body, slow motion and rigid and inflexible muscles. There is no cure for the disease.
The study, published in the journal Neurology, the biomarkers identified in the brain to measure how drug dealing only with the symptoms, but also neurological changes behind them.
Previous studies have used imaging techniques requiring the injection of a drug that crosses the blood brain barrier
Professor David Vaillancourt, of the University of Florida, said :. “Our technique is not based on the injection of a drug. Is not only non-invasive, it is far less expensive”.
brain scans five areas evaluated in 46 Parkinson’s patients who are key to movement and balance.
One year after the first scan showed decreased function in two brain areas -. the primary motor cortex and the putamen
Parkinson related disorders evaluated in the study also showed declines.
The 13 participants with multiple system atrophy – where tissue debris away – had reduced activity in three of the five areas, while 19 with progressive supranuclear palsy – conditions affecting the area top of the central nervous system – showed declines in five areas.
The experts found that the brain activity of 34 healthy control subjects did not change.
Dr. Debra Babcock, a program director at the National Institute of Neurological Disorders and Stroke in the US. . USA, explained: “for decades, the field has been searching for an effective biomarker for Parkinson’s disease
.” This study is an example of how biomarkers of brain imaging can be used to control the progression of Parkinson’s disease and other neurological disorders. “
The finding is based on a study by the University of Florida last year was the first to document the progressive deterioration of Parkinson through MRI (magnetic resonance imaging), showing an increase of liquid without restrictions in an area of the brain called nigra substania.
national institutes of study funded health from November the techniques used to test whether one approved for symptom relief drug can slow or stop the progressive degeneration.
Dr. Katrina Gwinn, also program director of the National Institute of neurological disorders and Stroke, described the effort to identify biomarkers as “an essential part of moving towards the development of treatments that affect not only the causes and symptoms of Parkinson’s disease.”